Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -800.76% | 119.59% | 29.23% | -42.28% | 12.54% |
| Total Depreciation and Amortization | 28.31% | -66.57% | -31.94% | -9.21% | -2.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 103.66% | -371.60% | -473.57% | 139.76% | -245.19% |
| Change in Net Operating Assets | 98.73% | -1,152.56% | -89.87% | 262.23% | -36.68% |
| Cash from Operations | -6.21% | -5.13% | -16.52% | 21.27% | -1.79% |
| Capital Expenditure | 99.56% | 31.08% | -258.06% | -18.47% | 33.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,027.03% | -110.07% | 172.50% | -11.57% | 10.19% |
| Cash from Investing | -27.44% | 30.57% | 171.56% | -11.82% | 10.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.57% | 538.46% | -31.58% | 533.33% | -75.00% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -100.00% | -- |
| Cash from Financing | -91.57% | 538.46% | -31.58% | -99.95% | 349,925.00% |
| Foreign Exchange rate Adjustments | -103.03% | 217.86% | -2,700.00% | 87.50% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.88% | 552.05% | 110.48% | -254.90% | 145.09% |